After sclerotherapy in cirrhosis, five-day survival without rebleeding was 85/98 with octreotide versus 72/101 with placebo (P = 0.009, difference CI 4–27 percent).
In plain wordsIn cirrhotic patients after sclerotherapy, octreotide increased survival without rebleeding versus placebo.
- Peptide
- Octreotide
- Outcome
- IncreaseSurvival without rebleeding at five days
- Study
n = 199
- Comparator
- Sclerotherapy plus placebo
- Analysis
- Primary
- Outcome group
- Gastrointestinal protection · Gastrointestinal
- Studied dose
- 25 micrograms per hour · continuous infusion · five daysAs given in this study (human).
Measurements
- Survival without rebleeding at 5 days
- 87 percent
- octreotide group, 85 of 98 patients
- Survival without rebleeding at 5 days
- 71 percent
- placebo group, 72 of 101 patients
- 95 percent confidence interval for the difference
- 4 to 27 percent
- octreotide minus placebo
- P value
- 0.009
- survival without rebleeding
Source sentences
After five days, the proportion of patients who had survived without rebleeding was higher in the octreotide group (85 of 98 patients, or 87 percent) than in the placebo group (72 of 101, or 71 percent; 95 percent confidence interval for the difference, 4 to 27 percent; P = 0.009).
2 context sentences(design, population, supporting numbers)
In a double-blind, prospective trial, 199 patients with cirrhosis and acute variceal bleeding who underwent emergency sclerotherapy were randomly assigned to receive a continuous infusion of octreotide (25 micrograms per hour) or placebo for five days.
The primary outcome measure was survival without rebleeding five days after sclerotherapy.